|
1
|
Lin T, Wang YE, Cui N, Li M, Wang R, Bai J, Fan Y, Xiong D, Xue F, Walsh PJ, Mao J. Nickel-Catalyzed Cross-Electrophile Coupling of 1,2,3-Benzotriazin-4(3 H)-ones with Aryl Bromides. J Org Chem 2022; 87:16567-16577. [PMID: 36455282 DOI: 10.1021/acs.joc.2c02246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
The nickel-catalyzed cross-electrophile coupling of 1,2,3-benzotriazin-4(3H)-ones with aryl bromides to generate a diverse array of ortho-arylated benzamide derivatives has been developed. The reaction displayed good functional group tolerance with Zn as the reductant. The key to this transformation is the ring opening of benzotriazinones, which undergo a denitrogenative process to obtain various benzamide derivatives (29 examples, 42-93% yield). The scalability of this transformation was demonstrated.
Collapse
Affiliation(s)
- Tingzhi Lin
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Yan-En Wang
- College of Science, Hebei Agricultural University, Baoding 071000, P. R. China
| | - Ning Cui
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Miaohui Li
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Rui Wang
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Jiahui Bai
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - YiRan Fan
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Dan Xiong
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| | - Fei Xue
- Institute of Material Physics & Chemistry, College of Science, Nanjing Forestry University, Nanjing 210037, P. R. China
| | - Patrick J Walsh
- Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States
| | - Jianyou Mao
- Technical Institute of Fluorochemistry, Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China
| |
Collapse
|
|
3
|
McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RAL, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JAM, Turner SD, Vickery RG. A Multivalent Approach to the Design and Discovery of Orally Efficacious 5-HT4 Receptor Agonists. J Med Chem 2009; 52:5330-43. [DOI: 10.1021/jm900881j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- R. Murray McKinnell
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Scott R. Armstrong
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - David T. Beattie
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Seok-Ki Choi
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Paul R. Fatheree
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Roland A. L. Gendron
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Adam Goldblum
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Patrick P. Humphrey
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Daniel D. Long
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Daniel G. Marquess
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - J. P. Shaw
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Jacqueline A. M. Smith
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - S. Derek Turner
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Ross G. Vickery
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| |
Collapse
|
|
4
|
Sonda S, Kawahara T, Katayama K, Sato N, Asano K. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT4 receptor agonists. Bioorg Med Chem 2005; 13:3295-308. [PMID: 15809165 DOI: 10.1016/j.bmc.2005.02.016] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2004] [Revised: 02/08/2005] [Accepted: 02/09/2005] [Indexed: 10/25/2022]
Abstract
It is thought that selective 5-HT(4) receptor agonists-such as 4-amino-5-chloro-2-methoxy-N-[1-(6-oxo-6-phenylhexyl)piperidin-4ylmethyl]benzamide (2)-have the ability to enhance both upper and lower gastrointestinal motility without any significant adverse effects. Modification of 2 was performed. Variation of the piperidin-4ylmethyl moiety of 2 led to a decrease in the binding affinity for the 5-HT(4) receptor. Following conversion of the carbonyl group on the benzoyl part to a hydroxyl or sulfoxide group, the binding affinity for the 5-HT(4) receptor was retained although the effect on defecation was reduced. Many of the 4-amino-5-chloro-2-methoxy-N-(piperidin-4ylmethyl)benzamides that had a ether or sulfide moiety in the side-chain part at the 1-position of the piperidine exhibited high affinity for the 5-HT(4) receptor. Among these, phenylthio 41c and benzylthio derivative 44 were selective 5-HT(4) receptor agonists, and had a similar effect on defecation to compound 2.
Collapse
Affiliation(s)
- Shuji Sonda
- Pharmaceutical Development Laboratories, Technology and Production Division, Mitsubishi Pharma Corporation, 14 Sunayama, Hasaki-machi, Kashima-gun, Ibaraki 314-0255, Japan.
| | | | | | | | | |
Collapse
|
|
5
|
Sonda S, Katayama K, Kawahara T, Sato N, Asano K. Synthesis and pharmacological properties of benzamide derivatives as selective serotonin 4 receptor agonists. Bioorg Med Chem 2004; 12:2737-47. [PMID: 15110855 DOI: 10.1016/j.bmc.2004.02.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2004] [Revised: 02/27/2004] [Accepted: 02/27/2004] [Indexed: 11/23/2022]
Abstract
A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamides with a polar substituent group at the 1-position of the piperidine ring was synthesized and evaluated for its effect on gastrointestinal motility. The benzoyl, phenylsulfonyl, and benzylsulfonyl derivatives accelerated gastric emptying and increased the frequency of defecation. One of them, 4-amino-N-[1-[3-(benzylsulfonyl)propyl]piperidin-4-ylmethyl]-5-chloro-2-methoxybenzamide (13a, Y-36912), was a selective 5-HT4 receptor agonist offering potential as a novel prokinetic with reduced side effects derived from 5-HT3- and dopamine D2 receptor-binding affinity. In the oral route of administration, this compound enhanced gastric emptying and defecation in mice, and has a possibility as a prokinetic agent, which is effective on both the upper and the lower gastrointestinal tract.
Collapse
Affiliation(s)
- Shuji Sonda
- Pharmaceutical Development Laboratories, Technology and Production Division, Mitsubishi Pharma Corporation, 14, Sunayama, Hasaki-machi, Kashima, Ibaraki 314-0255, Japan.
| | | | | | | | | |
Collapse
|